AC Immune FY2025 EPS Estimate Boosted by Leerink Partnrs

AC Immune (NASDAQ:ACIU) – Equities research analysts at Leerink Partnrs raised their FY2025 earnings estimates for shares of AC Immune in a report released on Wednesday, November 5th. Leerink Partnrs analyst M. Goodman now forecasts that the company will post earnings of ($0.86) per share for the year, up from their previous forecast of ($0.94). The consensus estimate for AC Immune’s current full-year earnings is ($0.62) per share. Leerink Partnrs also issued estimates for AC Immune’s Q4 2025 earnings at ($0.17) EPS, FY2026 earnings at ($0.62) EPS and FY2028 earnings at ($0.68) EPS.

AC Immune (NASDAQ:ACIU) last announced its quarterly earnings data on Tuesday, November 4th. The company reported ($0.20) earnings per share for the quarter, beating the consensus estimate of ($0.22) by $0.02. AC Immune had a negative return on equity of 49.35% and a negative net margin of 174.94%.The company had revenue of $0.95 million during the quarter, compared to analysts’ expectations of $0.81 million.

Other analysts have also issued reports about the stock. Zacks Research raised shares of AC Immune from a “strong sell” rating to a “hold” rating in a research report on Tuesday, September 9th. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of AC Immune in a report on Wednesday, October 8th. Finally, BTIG Research reiterated a “buy” rating and set a $8.00 price target on shares of AC Immune in a report on Tuesday. Two investment analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has issued a Sell rating to the company’s stock. Based on data from MarketBeat.com, AC Immune has a consensus rating of “Hold” and a consensus price target of $10.00.

AC Immune Stock Up 0.6%

ACIU stock opened at $3.45 on Friday. The company has a market cap of $346.41 million, a price-to-earnings ratio of -5.95 and a beta of 1.58. AC Immune has a twelve month low of $1.43 and a twelve month high of $4.00. The business has a 50 day moving average price of $2.91 and a two-hundred day moving average price of $2.28.

Hedge Funds Weigh In On AC Immune

A number of large investors have recently made changes to their positions in the company. Assenagon Asset Management S.A. acquired a new stake in AC Immune during the 3rd quarter worth approximately $549,000. Sei Investments Co. acquired a new position in AC Immune in the 2nd quarter valued at $51,000. Acadian Asset Management LLC increased its position in AC Immune by 87.1% during the 1st quarter. Acadian Asset Management LLC now owns 371,177 shares of the company’s stock worth $679,000 after buying an additional 172,796 shares during the period. BVF Inc. IL lifted its holdings in shares of AC Immune by 1.5% during the first quarter. BVF Inc. IL now owns 19,822,436 shares of the company’s stock worth $37,068,000 after buying an additional 300,000 shares in the last quarter. Finally, Banque Cantonale Vaudoise acquired a new stake in shares of AC Immune during the first quarter worth $50,000. Institutional investors own 51.36% of the company’s stock.

About AC Immune

AC Immune SA, a clinical stage biopharmaceutical company, discovers, designs, and develops medicines and diagnostic products for the prevention and treatment of neurodegenerative diseases associated with protein misfolding. Its SupraAntigen and Morphomer platforms are designed to generate vaccines, antibodies, and small molecules, which selectively interact with misfolded proteins that are common in a range of neurodegenerative diseases.